Explore the words cloud of the METACELL-TM project. It provides you a very rough idea of what is the project "METACELL-TM" about.
The following table provides information about the project.
Coordinator |
LUXCEL BIOSCIENCES LTD
Organization address contact info |
Coordinator Country | Ireland [IE] |
Project website | https://www.agilent.com/en/metacell |
Total cost | 3˙313˙827 € |
EC max contribution | 2˙459˙616 € (74%) |
Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2. (PRIORITY 'Industrial leadership') |
Code Call | H2020-FTIPilot-2016-1 |
Funding Scheme | IA |
Starting year | 2016 |
Duration (year-month-day) | from 2016-11-01 to 2019-04-30 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | LUXCEL BIOSCIENCES LTD | IE (Cork) | coordinator | 695˙481.00 |
2 | NCARDIA AG | DE (KOLN) | participant | 556˙437.00 |
3 | BMG LABTECH GMBH | DE (ORTENBERG) | participant | 492˙081.00 |
4 | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD | UK (OXFORD) | participant | 249˙268.00 |
5 | AGILENT TECHNOLOGIES IRELAND LIMITED | IE (DUBLIN) | participant | 240˙159.00 |
6 | IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE | UK (LONDON) | participant | 226˙187.00 |
'The healthcare industry is experiencing unprecedented rates of drug failure, long development times and high costs - because current lab tests and disease models (in vitro) don’t adequately predict drug effect in the patient (in vivo).
To address this “Challenge”, three leading EU SMEs; Luxcel Biosciences Ltd, Axiogenesis AG and BMG Labtech GmbH, are partnering to bring to market, a fully integrated targeted metabolomics Test Platform, comprising physiologically relevant in vitro cell assays and easy to use test kits, configured for use with the multimode fluorescence plate reader; instrumentation, which is installed in, or else is easily accessible to every cell biology lab globally.
The innovation “Solution' is made possible by Luxcel’s unique and patented optical nanosensor technology, and its integration to create entirely new ‘functionally-connected’ in vitro tests. The scope of the project is to finalize development of the cell-based assay platform towards market introduction, productise, pilot and demonstrate it with key opinion leaders; for modular product launch through the project and full launch early 2019.
Leveraging existing global sales channels, the three industrial partners are targeting revenues of EUR 15 million by 2023. In total, about 24-29 new jobs will be created by 2023; with 6 new jobs during the project. All three SMEs are passionate about the MetaCell-TM solution, and expect that a successful outcome will see them positioned as No. 1 in their respective fields in Europe and internationally. '
Sales Account Manager Recruitment | Other | 2020-01-30 18:37:58 |
Hosted ‘WEB-PORTAL’, developed and launched | Other | 2020-01-30 18:37:58 |
Take a look to the deliverables list in detail: detailed list of METACELL-TM deliverables.
year | authors and title | journal | last update |
---|---|---|---|
2019 |
M. Schwalfenberg, R. McGarrigle, C. Carey and J. Hynes Multiplexed Screening of Drug-Induced MitochondrialDysfunction and Cytotoxicity published pages: , ISSN: , DOI: |
2020-01-30 | |
2018 |
C. Wark, C. Carey, R. Kettenhofen, M. Schwalfenberg, J. Hynes The CLARIOstar® with ACU exposes cells to ischemiareperfusion conditions and monitors their oxygenation published pages: , ISSN: , DOI: |
2020-01-30 | |
2017 |
M. Potter, J. Hynes, A. Nijhuis, C. Carey, I. Hayes, C. Zois, A. Harris, H. Keun, K. Morten The importance of cellular oxygenation measurements in the analysis of hypoxia-induced signalling and related metabolic adaptation published pages: , ISSN: , DOI: |
2020-01-30 | |
2017 |
C. Carey, R. Kettenhofen, M. Schneider, J. Hynes Microplate-based ischemia-reperfusion model with real-time monitoring of cellular oxygenation and reactive oxygen species generation published pages: , ISSN: , DOI: |
2020-01-30 | |
2017 |
C. Carey, C. Bertinetti-Lapatki, R. Kettenhofen, A. Roth, J Hynes. Investigating Drug Induced Cardiomyocyte Dysfunction through Combined Analysis of Beating, Metabolic Flux and Cellular Oxygenation published pages: , ISSN: , DOI: |
2020-01-30 | |
2017 |
C. Carey, R. Kettenhofen, M. Schneider, M. Schwalfenberg, J. Hynes High-throughput in vitro ischemia-reperfusion model with real-time monitoring of cellular oxygenation and reactive oxygen species generation published pages: , ISSN: , DOI: |
2020-01-30 | |
2017 |
M. Schwalfenberg, R. McGarrigle, C. Carey, J. Hynes Modelling tumour hypoxia through parallel analysis of cellular oxygenation, glycolytic flux and mitochondrial function published pages: , ISSN: , DOI: |
2020-01-30 | |
2017 |
C. Carey, T. Xinru, Y. Will, J. Hynes A functional high-throughput screen for drug-induced modulation of fatty acid oxidation published pages: , ISSN: , DOI: |
2020-01-30 | |
2016 |
D.L. Hoffman, C.A. Peters , J. Hynes The Measurement of Cellular Bioenergetics at Defined Steady-State Oxygen Concentrations: A Novel Microplate Based Method published pages: , ISSN: , DOI: |
2020-01-30 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "METACELL-TM" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "METACELL-TM" are provided by the European Opendata Portal: CORDIS opendata.